We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Merges Patient Data with Blood Test Results to Detect Heart Failure

By LabMedica International staff writers
Posted on 20 Jun 2022

Acute heart failure is a life-threatening condition caused when the heart is suddenly unable to pump blood around the body. More...

It affects millions of people and accounts for a large percentage of all unplanned hospital admissions. Diagnosis is difficult because symptoms, such as shortness of breath and leg swelling, occur in many other illnesses. Previous research has shown that patients who are diagnosed quickly benefit the most from treatment. Now, research suggests that using artificial intelligence (AI) can help diagnose acute heart failure with more accuracy than current blood tests alone.

The research conducted by The University of Edinburgh (Edinburgh, UK) found that using AI to combine patient data with results from a test for levels of a protein made by the heart could help doctors spot heart failure sooner and improve patient care. Researchers combined data from 10,369 patients with suspected acute heart failure to develop a tool - called CoDE-HF – to inform clinicians’ decisions. CoDE-HF uses AI to combine routinely collected patient information with results from a blood test for the heart protein NT-proBNP to produce an estimate of whether they suffered heart failure. The current recommended diagnosis method is to test to see if levels of NT-proBNP are below a certain cut-off value, but this is not widely used as levels can vary depending on an individual’s age, weight and other health conditions.

As well as spotting acute heart failure more accurately than heart protein blood tests on their own, CoDE-HF was especially precise in difficult to diagnose patient groups - such as older people and those with pre-existing medical conditions. The team is currently conducting further studies to understand how this decision-support tool will work in the hospital environment and influence patient outcomes.

“Heart failure can be a very challenging diagnosis to make in practice. We have shown that CoDE-HF, our decision-support tool, can substantially improve the accuracy of diagnosing heart failure compared to current blood tests,” said Dr. Ken Lee, cardiology specialist registrar and clinical lecturer at the University of Edinburgh.

“Our study demonstrates that the application of artificial intelligence in healthcare has major potential to help doctors deliver more personalized patient care,” added Dimitrios Doudesis, research fellow and data scientist at the University of Edinburgh.

“The application of artificial intelligence in decision-support tools as CoDE-HF to deliver more personalized care is particularly important given our ageing patient population who are living longer with more pre-existing medical conditions. We are currently conducting further studies to identify ways to implement CoDE-HF effectively in routine care,” stated Professor Nicholas Mills, British Heart Foundation professor of cardiology at the University of Edinburgh and consultant cardiologist.

Related Links:
The University of Edinburgh 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.